HeartBeam, Inc. develops medical technology for ambulatory cardiac monitoring, centered on a patented cable-free 3D ECG platform that captures signals from three non-coplanar dimensions and synthesizes a 12-lead ECG. News commonly covers the FDA-cleared HeartBeam System for arrhythmia assessment, limited commercial launch activity, preventive cardiology and concierge practice deployments, AI-ECG collaboration, and development of on-demand patch and heart attack detection initiatives.
Corporate updates also include financial results and common-stock financing used to support commercialization, product development, AI capabilities, working capital, and general corporate purposes.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
HeartBeam, Inc. (NASDAQ: BEAT) announced its acquisition of LIVMOR’s assets, including the FDA-cleared Halo+™ Atrial Fibrillation Detection System, enhancing its remote monitoring capabilities. The partnership with Evolve Manufacturing aims to develop the HeartBeam AIMIGo 12-Lead electrocardiogram device, with initial market testing slated for Q4 2023 post-FDA clearance. The company received European patents protecting its technology, facilitating expansion. Financial results show a net loss of $3.7 million for Q4 2022, up from $2.1 million a year prior, with cash reserves at $3.6 million. Management projects further advancements in FDA submissions in 2023.
HeartBeam, Inc. (NASDAQ: BEAT) has acquired substantially all assets of LIVMOR, a digital health solutions company, enhancing its capabilities in remote cardiac monitoring. This acquisition includes the FDA-cleared Halo+™ Atrial Fibrillation Detection System, the first prescription wearable for continuous monitoring of cardiac rhythms. Founded in 2016, LIVMOR's technology has been deployed in the VA Healthcare System in Dallas, Texas. The strategic move is expected to integrate LIVMOR's cloud-based software with HeartBeam's existing solutions, potentially improving patient outcomes and reducing healthcare costs. Financial terms remain undisclosed.
HeartBeam, Inc. (NASDAQ: BEAT) announced a senior leadership change with Robert Eno stepping in as Executive Vice President and Chief Business Officer, taking over from Jon Hunt, who will now serve as a strategic advisor and consultant. This transition is effective March 15, 2023. The company is preparing for key milestones in 2023, including FDA clearance for the HeartBeam AIMI™ system and submission for the AIMIGo™ product. Dr. Hunt has played a crucial role in product development and market introduction efforts, while Eno is expected to bring fresh perspectives for commercialization strategies.